Qualigen Therapeutics, Inc.
QLGN
$5.23
-$0.36-6.44%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.69M | -2.65M | -855.80K | -1.79M | -- |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | 101.50K | 191.30K | -- |
| Total Other Non-Cash Items | 294.70K | 120.80K | -554.20K | 503.70K | -- |
| Change in Net Operating Assets | 292.60K | 936.00K | -961.00K | -700.80K | -- |
| Cash from Operations | -1.10M | -1.59M | -2.27M | -1.80M | -1.47M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.21M | -305.00K | -1.01M | -1.25M | -- |
| Cash from Investing | -1.21M | -305.00K | -1.01M | -1.25M | 350.00K |
| Total Debt Issued | 2.75M | 750.00K | 0.00 | 2.00M | -- |
| Total Debt Repaid | -132.00K | -- | -499.00K | -2.00M | -- |
| Issuance of Common Stock | -- | -- | 0.00 | 3.32M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 4.56M | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.61M | 750.00K | 4.06M | 3.32M | 1.15M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | 0.00 | 0.00 | -- | -- | -- |
| Net Change in Cash | 301.40K | -1.14M | 786.50K | 269.50K | 25.50K |